Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

BACKGROUND: Safety of rechallenge of immune checkpoint inhibitor (ICI) after grade ≥2 immune-related adverse events (irAEs) leading to ICI discontinuation remains unclear. METHODS: All adverse drug reactions involving at least one ICI reported up to December 31, 2019 were extracted from the French p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Allouchery, Marion, Lombard, Thomas, Martin, Mickael, Rouby, Franck, Sassier, Marion, Bertin, Celia, Atzenhoffer, Marina, Miremont-Salame, Ghada, Perault-Pochat, Marie-Christine, Puyade, Mathieu
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Oncolytic and Local Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768965/
https://ncbi.nlm.nih.gov/pubmed/33428586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados